Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.99 USD | +1.01% | +0.59% | -45.74% |
03:34am | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
Apr. 22 | Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.74% | 2.8B | |
-0.02% | 42.11B | |
+49.22% | 40.08B | |
+5.04% | 40B | |
-11.32% | 26.87B | |
+5.25% | 24.58B | |
-23.83% | 18.44B | |
-1.62% | 11.94B | |
+22.75% | 11.66B | |
+6.44% | 11.01B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- ACADIA Pharmaceuticals Phase 3 Trial Shows Improvement in Rett Syndrome Patients' Core Symptoms -- Shares Surge in Pre-Market